CPRX News and Press, Catalyst Pharmaceuticals Inc. From 11/26/19

CORAL GABLES, Fla., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologic...

Investment Thesis Catalyst Pharmaceuticals ( CPRX ) has had an eventful year. The company has launched a new drug after 5 years in development, faced criticism for its perceived excessive pricing point, lost its exclusivity after the FDA approved a rival treatment, launched a lawsuit against...

Catalyst Pharmaceuticals (NASDAQ: CPRX) , a small-cap rare disease specialist, reported its third-quarter earnings after the bell on Tuesday. Yesterday, the drugmaker's shares closed down by 7.5% on over three times the average daily volume. The stock dipped in response to two key developm...

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2019 Results Earnings Conference Call November 13, 2019, 08:30 AM ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Steve Miller - Chief Operating Officer and Chief Scien...

Image source: The Motley Fool. Catalyst Pharmaceuticals Inc   (NASDAQ: CPRX) Q3 2019 Earnings Call Nov 13, 2019 , 8:30 a.m. ET Operator Continue reading

In response to management announcing mixed third-quarter results and sharing tepid guidance, shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) , a commercial-stage biopharma focused on rare diseases, dropped 12% as of 11:03 a.m. EST on Wednesday. Here are some headline numbers from the quart...

Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q3 GAAP EPS of $0.13 beats by $0.02 . Revenue of $30.9M misses by $2.29M . Shares -8.4% . Press Release More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,

- Firdapse ® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of $135 Million to $155 Million for FY 2020 ...

Catalyst Pharmaceuticals (NASDAQ: CPRX ) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close. The consensus EPS Estimate is $0.11 (+237.5% Y/Y) and the consensus Revenue Estimate is $33.19M Over the last 2 years, cprx has beaten EPS estimates 50...

ADPT , ADT , BREW , CBPX , CDLX , CPRX , DDOG , DOX , HALO , HCAT , HIIQ , HTHT , HUYA , KWR , MCRN , MTSI , OMER , PTE , RUN , SDC , SENS , SSTI , SWKS , TLRY , TVTY , TWOU , VRAY , VREX , YY For Seeking Alpha's full earnings season calendar, click here . ...